stockrowEdgewise Therapeutics, Inc.
EWTX Healthcare Biotechnology
- EPS
- +2,846.5%
- Free cash flow
- −30.2%
Quarter to September 2026, against a year earlier
Follow EWTX
Alert me
Edgewise Therapeutics, Inc. (EWTX) Return on equity
Edgewise Therapeutics, Inc.'s return on equity over the twelve months to 30 September 2026 was 92.2%, up 126.3 percentage points from fiscal 2025 (−34.2%). Over the past ten years it has ranged from −35.5% (fiscal 2021) to −14.2% (fiscal 2020); the current reading is higher than 50% of that period. That is above the Biotechnology industry median of −50.1% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −34.2% | 0.21 |
| FY2024 | −34.4% | (4.30) |
| FY2023 | −30.1% | (8.32) |
| FY2022 | −21.8% | 13.75 |
| FY2021 | −35.5% | (21.32) |
| FY2020 | −14.2% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ARQT Arcutis Biotherapeutics, Inc. compare | 14.9% |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −8.08% |
| ABCL AbCellera Biologics Inc. compare | −17.3% |
| TNGX Tango Therapeutics, Inc. compare | −21.3% |
| IOVA Iovance Biotherapeutics, Inc. compare | −29.1% |
| RLAY Relay Therapeutics, Inc. compare | −36.8% |
| EWTX Edgewise Therapeutics, Inc. | −38.0% |
| XENE Xenon Pharmaceuticals Inc. compare | −43.6% |
| DFTX Definium Therapeutics, Inc. compare | −64.1% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)